Regorafenib-pembrolizumab vs. TACE/TARE in Intermediate Stage HCC Beyond Up-to-7

Stopped The trial ended earlier than planned due to slow enrolment, which has made it unfeasible to achieve the target sample size within a reasonable timeframe. Consequently, a business decision has been made to discontinue funding for the trial.

Conditions

• Carcinoma, Hepatocellular

Interventions

• DRUG: Regorafenib in combination with pembrolizumab
• PROCEDURE: Loco-regional therapy

Sponsor

Translational Research in Oncology

Collaborators

• [object Object]